Literature DB >> 11326005

Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase.

F Luzzaro1, E Mantengoli, M Perilli, G Lombardi, V Orlandi, A Orsatti, G Amicosante, G M Rossolini, A Toniolo.   

Abstract

From November 1998 to August 1999, a large outbreak occurred in the general intensive care unit of the Ospedale di Circolo in Varese (Italy), caused by Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase. A total of 108 clinical isolates of P. aeruginosa resistant to broad-spectrum cephalosporins were recovered from 18 patients. Epidemic isolates were characterized by synergy between clavulanic acid and ceftazidime, cefepime, and aztreonam. Isoelectric focusing of crude bacterial extracts detected two nitrocefin-positive bands with pI values of 8.0 and 5.3. PCR amplification and characterization of the amplicons by restriction analysis and direct sequencing indicated that the epidemic isolates carried a bla(PER-1) determinant. The outbreak was of clonal origin as shown by pulsed-field gel electrophoresis analysis. This technique also indicated that the epidemic strain was not related to three other PER-1-positive isolates obtained at the same hospital in 1997. Typing by enterobacterial repetitive intergenic consensus-PCR showed that minor genetic variations occurred during the outbreak. The epidemic strain was characterized by a multiple-drug-resistance phenotype that remained unchanged over the outbreak, including extended-spectrum cephalosporins, monobactams, aminoglycosides, and fluoroquinolones. Isolation of infected patients and appropriate carbapenem therapy were successful in ending the outbreak. Our report indicates that the bla(PER-1) resistance determinant may become an emerging therapeutic problem in Europe.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11326005      PMCID: PMC88040          DOI: 10.1128/JCM.39.5.1865-1870.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

Review 1.  Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units.

Authors:  D J Flournoy; R L Reinert; C Bell-Dixon; C A Gentry
Journal:  Am J Infect Control       Date:  2000-06       Impact factor: 2.918

2.  Extended-spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa.

Authors:  L Poirel; E Ronco; T Naas; P Nordmann
Journal:  Clin Microbiol Infect       Date:  1999-10       Impact factor: 8.067

Review 3.  Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations.

Authors:  L M Bush; C C Johnson
Journal:  Infect Dis Clin North Am       Date:  2000-06       Impact factor: 5.982

4.  Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups.

Authors:  H Hanberger; J A Garcia-Rodriguez; M Gobernado; H Goossens; L E Nilsson; M J Struelens
Journal:  JAMA       Date:  1999-01-06       Impact factor: 56.272

5.  Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa.

Authors:  J Rello; P Jubert; J Vallés; A Artigas; M Rué; M S Niederman
Journal:  Clin Infect Dis       Date:  1996-11       Impact factor: 9.079

Review 6.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 7.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

8.  Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.

Authors:  E Mansouri; J Gabelsberger; B Knapp; E Hundt; U Lenz; K D Hungerer; H E Gilleland; J Staczek; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

9.  Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa.

Authors:  P Nordmann; E Ronco; T Naas; C Duport; Y Michel-Briand; R Labia
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  27 in total

1.  Emerging extended-spectrum beta-lactamases in Proteus mirabilis.

Authors:  Laura Pagani; Roberta Migliavacca; Lucia Pallecchi; Cecilia Matti; Ernesto Giacobone; Gianfranco Amicosante; Egidio Romero; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  High prevalence of PER-1 extended-spectrum beta-lactamase-producing Acinetobacter spp. in Korea.

Authors:  Dongeun Yong; Jong Hee Shin; Sinyoung Kim; Youngsik Lim; Jong Hwa Yum; Kyungwon Lee; Yunsop Chong; Adolf Bauernfeind
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Simple microdilution test for detection of metallo-beta-lactamase production in Pseudomonas aeruginosa.

Authors:  Roberta Migliavacca; Jean-Denis Docquier; Claudia Mugnaioli; Gianfranco Amicosante; Rossana Daturi; Kyungwon Lee; Gian Maria Rossolini; Laura Pagani
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals.

Authors:  F Luzzaro; E F Viganò; D Fossati; A Grossi; A Sala; C Sturla; M Saudelli; A Toniolo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-12-11       Impact factor: 3.267

Review 5.  Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact.

Authors:  Gerhard F Weldhagen; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

6.  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Authors:  Mario Tumbarello; Maurizio Sanguinetti; Eva Montuori; Enrico M Trecarichi; Brunella Posteraro; Barbara Fiori; Rita Citton; Tiziana D'Inzeo; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

7.  Clonal relatedness and conserved integron structures in epidemiologically unrelated Pseudomonas aeruginosa strains producing the VIM-1 metallo-{beta}-lactamase from different Italian hospitals.

Authors:  Maria Letizia Riccio; Lucia Pallecchi; Jean-Denis Docquier; Stefania Cresti; Maria Rosaria Catania; Laura Pagani; Cristina Lagatolla; Giuseppe Cornaglia; Roberta Fontana; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

8.  Extended-spectrum beta-lactamase CTX-M-1 in Escherichia coli isolates from healthy poultry in France.

Authors:  Delphine Girlich; Laurent Poirel; Alessandra Carattoli; Isabelle Kempf; Marie-Frédérique Lartigue; Alessia Bertini; Patrice Nordmann
Journal:  Appl Environ Microbiol       Date:  2007-05-18       Impact factor: 4.792

9.  Nosocomial infections caused by multidrug-resistant isolates of pseudomonas putida producing VIM-1 metallo-beta-lactamase.

Authors:  Gianluigi Lombardi; Francesco Luzzaro; Jean-Denis Docquier; Maria Letizia Riccio; Mariagrazia Perilli; Alessandra Colì; Gianfranco Amicosante; Gian Maria Rossolini; Antonio Toniolo
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

10.  Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; Laura Zamorano; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.